In 2020, a major clinical trial called the STEP (Semaglutide Treatment Effect in People with Obesity) program evaluated the efficacy of Semaglutide for weight loss in a large cohort of adults with obesity. The trial involved more than 4,500 participants with a BMI of 30 or greater or a BMI of 27 or greater with at least one weight-related comorbidity (such as high blood pressure or type 2 diabetes).
The trial compared the effects of Semaglutide to a placebo, with participants receiving either a weekly injection of Semaglutide or a placebo injection. The study lasted for 68 weeks.
The results showed that Semaglutide led to significant weight loss compared to the placebo. Participants who received Semaglutide lost an average of 15.3% of their body weight, compared to 2.4% for those who received the placebo. Additionally, a higher proportion of participants in the Semaglutide group achieved clinically significant weight loss (defined as losing at least 5% of their body weight) compared to the placebo group (86.4% vs. 31.5%).
The study also found that Semaglutide led to improvements in other health measures, including blood pressure, lipid levels, and glycemic control (for participants with type 2 diabetes).
Overall, the study demonstrated that Semaglutide is an effective and well-tolerated treatment for weight loss in adults with obesity. The medication was associated with significant weight loss and improvements in other health measures. These findings suggest that Semaglutide may be a valuable tool for addressing the growing problem of obesity and its associated health risks. However, it’s important to note that Semaglutide is a prescription medication and should only be used under the guidance of a healthcare professional.